Once-Weekly TransCon CNP (Navepegritide) in Children With Achondroplasia (ACcomplisH): A Phase 2, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
Once-Weekly Lonapegsomatropin (TransCon hGH) Added to Once-Weekly Navepegritide (TransCon CNP) in Children With Achondroplasia: 26-Week Results from the Phase 2 COACH Trial
Improvements in Lower Extremity Alignment are Associated With Physical Functioning in Children With Achondroplasia Treated With Navepegritide: 52-Week Results From the ApproaCH Trial
This website is a self-service hub of scientific information, educational resources, and published clinical data related to Ascendis Pharma’s treatments and therapeutic areas of interest. This website is intended for healthcare professionals in the United States and its territories. By accessing and searching across this website, you confirm the unsolicited nature of your inquiry and interest. The website is made available by Ascendis Pharma’s US Medical Affairs organization and is provided as a resource for informational, non-promotional, and scientific exchange purposes only.
This website may contain information about products or uses that have not been approved by the U.S. Food and Drug Administration (FDA) and does not establish the safety or efficacy of these products or uses. There is no guarantee that investigational products and uses will receive FDA approval. The content of this site is not medical advice. Ascendis Pharma is unable to provide treatment recommendations outside of the approved product label. Treatment decisions should always be based on institutional standards and the treating healthcare professional’s clinical judgement based on the individual patient’s needs. Please review the full prescribing information for safety information and directions for use before prescribing medications. By selecting the option below, you acknowledge that you are a US healthcare professional.
Please report any adverse events related to any of our products by calling us at 1-844-442-7236.
You are encouraged to report side effects of prescription drugs to the FDA.
Call 1-800-FDA-1088 or visit www.fda.gov/medwatch.
You are now leaving the Ascendis Pharma US Medical Website
You are now leaving the Ascendis Pharma US Medical Website. Third-party websites are not owned, endorsed, or controlled by Ascendis Pharma. Ascendis Pharma is not responsible for the content on third-party websites. Any opinions, claims, or comments expressed therein should not be attributed to Ascendis Pharma.
